Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. ().
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616 | PMC |
| http://dx.doi.org/10.1016/j.jaccas.2019.09.026 | DOI Listing |
Publication Analysis
Top Keywords
solid organ
12
lipid-lowering therapies
8
organ transplantations
8
pcsk9 inhibitors
4
inhibitors solid
4
organ transplantation
4
transplantation recipients
4
recipients standard
4
standard lipid-lowering
4
therapies solid
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!